No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Eva Medtec Launches Neuroglide™ Pain Relief and Recovery System

With Early Release of 250 Units for Online Purchase

Editor: What To Know

  • Neuroglide’s patented system includes a Controller Unit, disruptive new valve module technology, and unique inflatable air channels which have been precisely engineered to deliver the proven benefits of MLD therapy in the comfort of one’s home, relieving pain without the need for pharmaceuticals or expensive in-person sessions while offering improved recovery and performance, relaxation, and stress relief.
  • The Neuroglide Back/Neck Pad is the first of a system of automated therapy devices that provide effective, convenient, and sustainable pain management solutions for people living with chronic pain, who need to relax, relieve and recover.
  • Sporting an FDA clearance for pain relief, a limited, 250-unit release of this innovative neck and back pain therapy device can now be purchased here, with a $250.

Eva Medtec, Inc. is excited to announce that its flagship product, the Neuroglide Back/Neck Pad, is available for purchase by the general public.

Sporting an FDA clearance for pain relief, a limited, 250-unit release of this innovative neck and back pain therapy device can now be purchased here, with a $250.00 discount.

The Neuroglide Back/Neck Pad is the first of a system of automated therapy devices that provide effective, convenient, and sustainable pain management solutions for people living with chronic pain, who need to relax, relieve and recover.

The technology is designed to emulate a therapeutic modality called manual lymphatic drainage (MLD). MLD triggers the body’s parasympathetic nervous system, activating powerful natural relaxation and pain relief pathways.

Neuroglide’s patented system includes a Controller Unit, disruptive new valve module technology, and unique inflatable air channels which have been precisely engineered to deliver the proven benefits of MLD therapy in the comfort of one’s home, relieving pain without the need for pharmaceuticals or expensive in-person sessions while offering improved recovery and performance, relaxation, and stress relief.

Eva Medtec founder/CEO and Neuroglide inventor, Irene Waldridge, previously founded Tactile Medical, where she held four patents as the inventor of the Flexitouch® System for the treatment of lymphedema and venous insufficiency. Tactile Medical is currently valued at about $1B on revenues approximating $190M.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy